|
KMID : 1134120210240040359
|
|
Journal of Breast Cancer
2021 Volume.24 No. 4 p.359 ~ p.366
|
|
|
Tumor-Infiltrating Lymphocytes in Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer Receiving Neoadjuvant Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab
|
|
Ha Joo-Young
Kim Jeong-Eun
Lee Hee-Jin
Jeong Jae-Ho
Ahn Jin-Hee
Jung Kyung-Hae
Gong Gyung-Yub
Chae Eun-Young
Kim Hak-Hee
Chung Il-Yong
Ko Beom-Seok
Kim Sung-Bae
|
|
|
Abstract
|
|
|
Purpose: The tumor-infiltrating lymphocytes (TILs) expression in breast cancer is a positive prognostic marker for certain breast cancer subtypes. We evaluated the efficacy of dual anti-human epidermal growth factor receptor 2 (HER2) blockade in HER2-positive breast cancer and hypothesized that high TILs tumors are associated with better outcomes.
Methods: A total of 176 patients who were treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCHP) between December 2015 and December 2018 were reviewed. They were grouped based on a cut-off value of the stromal TILs grade (≤ 20% TILs, > 20% TILs).
Results: In total, 107 patients (60.8%) achieved pathological complete response (pCR). Hormone receptor (HR)-negativity (p = 0.001) and a high TILs grade (p = 0.022) were independent predictors of pCR. Among the HR-negative patients, high TILs tumors were significantly associated with pCR (p = 0.035).
Conclusion: HR status and the TILs grade are significantly correlated with pCR in dual anti-HER2 neoadjuvant therapy. The evaluation of the TILs at baseline may be beneficial for predicting pCR in HER2-positive breast cancer.
|
|
|
KEYWORD
|
|
|
Receptor, ErbB-2, Neoadjuvant therapy, Lymphocytes, Tumor microenvironment
|
|
|
FullTexts / Linksout information
|
|
|
|
|
Listed journal information
|
|
   
|